Jianxiang Wang – VJRegenMed

Progression of CAR-T trials in China

Marta Palhas — Fri, 26 Feb 2021 14:08:26 +0000

Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, gives an overview of the current CAR T-cell trial activities in China. Prof. Wang highlights the progression of the bispecific CAR-T targeting CD19 and CD22 and the BCMA and CD19 bispecific CAR-T, both manufactured in the FasT CAR-T platform. A novel TCR-based extracellular complex, STAR (synthetic TCR and antigen receptor), is being investigated in China. STAR T-cells may have improved persistence after infusion. Lastly, Prof. Wang discusses a new CD7-CAR T-cell product against T-cell malignancies. This interview took place during the 3rd European CAR T-cell Meeting.

CAR-T trials to watch in China

Marta Palhas — Fri, 26 Feb 2021 14:08:26 +0000

Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, shares key Chinese CAR-T clinical trials to look out for. Two different clinical trials investigating CD19 CAR T-cells for non-Hodgkin lymphoma are almost completed, and approval is expected soon in China. Additionally, clinical trials studying BCMA CAR T-cell therapy for multiple myeloma are also making good progress. Lastly, Prof. Wang highlights clinical trials evaluating CD19 CAR T-cells for relapsed/refractory acute lymphoblastic leukemia (ALL), particularly for adults. This interview took place during the 3rd European CAR T-cell Meeting.